Gemina Laboratories Ltd.
GLABF
$0.528
-$0.0839-13.71%
OTC PK
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 108.75% | -26.70% | -26.73% | -28.51% | -17.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.70% | -6.26% | -43.27% | -53.88% | -47.04% |
| Operating Income | -27.70% | 6.26% | 43.27% | 53.88% | 47.04% |
| Income Before Tax | -77.21% | 26.42% | 40.59% | 51.80% | 61.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -77.21% | 26.42% | 40.59% | 51.80% | 61.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -77.21% | 26.42% | 40.59% | 51.80% | 61.12% |
| EBIT | -27.70% | 6.26% | 43.27% | 53.88% | 47.04% |
| EBITDA | -28.12% | 5.94% | 43.42% | 54.03% | 47.26% |
| EPS Basic | -78.67% | 27.35% | 40.37% | 54.14% | 66.67% |
| Normalized Basic EPS | -80.85% | 27.40% | 41.58% | 53.98% | 66.67% |
| EPS Diluted | -78.67% | 27.35% | 40.37% | 54.14% | 66.67% |
| Normalized Diluted EPS | -80.85% | 27.40% | 41.58% | 53.98% | 66.67% |
| Average Basic Shares Outstanding | -0.35% | 1.61% | 0.29% | 5.07% | 16.47% |
| Average Diluted Shares Outstanding | -0.35% | 1.61% | 0.29% | 5.07% | 16.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |